FUSION PROTEIN TARGETING BOTH CD3 AND CD137, PREPARATION METHOD THEREFOR AND USE THEREOF
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Oct 24, 2024
app pub date -
Nov 11, 2021
filing date -
Nov 11, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present application provides a fusion protein, containing: an anti-CD137 antibody capable of specifically binding to a CD137 molecule or an antigen binding fragment thereof; an anti-CD3 antibody capable of specifically binding to a CD3 molecule or an antigen binding fragment thereof; and a first peptide linker and a second peptide linker. The present application also provides a nucleic acid encoding the fusion protein, an expression vector containing the nucleic acid, a host cell containing the nucleic acid or the expression vector, a method for preparing the fusion protein, a pharmaceutical composition containing the fusion protein, and a use of the fusion protein.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully